𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Superinfection of chimpanzees carrying hepatitis C virus of genotype II/1b with that of genotype III/2a or I/1a

✍ Scribed by Hiroaki Okamoto; Shunji Mishiro; Hajime Tokita; Fumio Tsuda; Yuzo Miyakawa; Makoto Mayumi

Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
672 KB
Volume
20
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Mutations in the NS5A gene of hepatitis
Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b
✍ HofgΓ€rtner, Wolfgang T.; Polyak, Stephen J.; Sullivan, Daniel G.; Carithers, Rob πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 310 KB πŸ‘ 3 views

Previous studies from Japan have described an association between a conserved sequence within the hepatitis C virus (HCV) genome and resistance to interferon (IFN) therapy for patients infected with HCV genotype 1b [

The hepatitis C virus core protein of ge
The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms
✍ Valerio Pazienza; Sophie ClΓ©ment; Paolo Pugnale; StΓ©phanie Conzelman; Michelange πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 602 KB

Both molecular and clinical evidence support a link between HCV infection and insulin resistance. We examined the in vitro interaction between the HCV core protein of genotypes 3a and 1b with the insulin-signaling pathway. We measured the expression levels of insulin receptor substrate 1 (IRS-1), IR

Phase 1b study of pegylated interferon l
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection
✍ Andrew J. Muir; Mitchell L. Shiffman; Atif Zaman; Boris Yoffe; Andrew de la Torr πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 678 KB

Interferon lambda 1 (IFN-k1) is a type III IFN that produces intracellular responses similar to those of IFN-a but in fewer cell types because of differences in the receptor distribution pattern, and this could potentially result in an improved safety profile. This was an open-label three-part study